AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 422029
Drug: Neogynon (D‐Norgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neogynon (D‐Norgestrel 0.25 mg, ethinyloestradiol 50 mcg)
Trial: 422029
Drug: Lyndiol (Lynestrenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyndiol (Lynestrenol 2.5 mg with ethinyloestradiol 50 mcg)
Trial: 26260780
Drug: Rumination-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rumination-focused cognitive behaviour therapy
Trial: 21936344
Drug: Tianeptine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (3 x 12.5 mg daily)
Trial: 18421047
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg/m2/d)
Trial: 18421047
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg/m2/d) in low-risk arm
Trial: 18421047
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg/m2/d) in standard/high-risk arm
Trial: 18421047
Drug: Dexamethasone pharmacokinetics
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone pharmacokinetics
Trial: 16025957
Drug: Danning Tablet
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danning Tablet (DNT)
Trial: 12660056
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care (3-month multicomponent intervention led by a non-medical health worker including psychoeducational group intervention, structured follow-up, and drug treatment for severe depression)
Trial: 8551753
Drug: Heparin-coated perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated perfusion circuits (Carmeda process; Medtronic Cardiopulmonary)
Trial: 8551753
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic heparin (300 U/kg)
Trial: 1867303
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 1% suspension
Trial: 1867303
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 1% suspension (after placebo)
Trial: 7068283
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg administered thrice daily
Trial: 7068283
Drug: Amoxycillin administered
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin administered thrice daily
Trial: 30191395
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy with a written checklist for parents to fully complete (Group II)
Trial: 30191395
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy as a written guideline (Group I)
Trial: 30191395
Drug: Desmopressin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin treatment plus verbal behavioural therapy (Group III)
Trial: 26467797
Drug: Preoperative CA19‐9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative CA19‐9 ≥300 U/ml
Trial: 18555556
Drug: High-dose epirubicin/cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epirubicin/cisplatin
Trial: 17697200
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg q.d.s.
Trial: 17697200
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg b.d.
Trial: 17697201
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 or 80 mg)
Trial: 8328192
Drug: rt-PA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (100 mg in 90 min)
Trial: 25177814
Drug: Meldonium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meldonium (500 mg/day) for 3 months
Trial: 20350924
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine and Pioglitazone
Trial: 7483804
Drug: Meningococcal group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal group B (15:P1.3) outer membrane protein vaccine, two doses six weeks apart
Trial: 7483804
Drug: Meningococcal group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal group B (15:P1.3) outer membrane protein vaccine
Trial: 7483804
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Menomune, A, C, Y and W135 meningococcal polysaccharide vaccine)
Trial: 2278224
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (0.2 mg/kg at 24th, 36th, and 60th hour of age)
Trial: 2278224
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml 0.33% saline in 5% G/W solution at the same schedule)
Trial: 29723441
Drug: Hydrocodone extended-release
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone extended-release (ER) 45 mg
Trial: 29723441
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro® ER
Trial: 25568560
Drug: Capsules containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 500 mg of powdered sumac fruits, three times a day for one month
Trial: 22677302
Drug: 75 mg/ml
RxNorm normalized name: urea 375 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/ml diclofenac sodium HPβCD (i.m.)
Trial: 22677302
Drug: 75 mg/ml
RxNorm normalized name: urea 375 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/ml diclofenac sodium HPβCD (s.c.)
Trial: 22677302
Drug: 25, 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 50, or 75 mg/ml diclofenac sodium HPβCD (s.c.)
Trial: 22677302
Drug: Voltaren® 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voltaren® 75 mg/3 ml (i.m.)
Trial: 20194850
Drug: Cap 45
RxNorm normalized name: TSD HP ProTect Cap 45 mm Lblue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap 45 (radiotherapy 45 Gy/25 fractions with concurrent capecitabine 800 mg/m² twice daily 5 days per week)
Trial: 20194850
Drug: Capox 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capox 50 (radiotherapy 50 Gy/25 fractions with capecitabine 800 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly)
Trial: 18071094
Drug: Antidepressants plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants plus counseling
Trial: 18071094
Drug: Treatment offered
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment offered
Trial: 15900097
Drug: Low-dose FK506
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FK506
Trial: 11988250
Drug: Ibuprofen prophylaxis
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen prophylaxis for patent ductus arteriosus
Trial: 7608428
Drug: Zatebradine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatebradine (5 mg twice a day)
Trial: 342622
Drug: Monovalent whole‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent whole‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Trial: 342622
Drug: Monovalent split‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent split‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Trial: 342622
Drug: Whole‐virus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐virus vaccine
Trial: 6459776
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 0.125 mg
Trial: 6459776
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 0.25 mg
Trial: 6459776
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 0.5 mg
Trial: 31500629
Drug: Combination containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract
Trial: 22343090
Drug: Antidepressants (escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (escitalopram or amitriptyline)
Trial: 7796781
Drug: AcOH (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AcOH (olive oil plus 1 g acetic acid in the form of vinegar)
Trial: 7796781
Drug: AcOH +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AcOH + Bread (olive oil plus 1 g acetic acid in the form of vinegar followed by 50 g carbohydrate portions of white bread)
Trial: 7796781
Drug: Blank +
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank + Bread (olive oil without vinegar followed by 50 g carbohydrate portions of white bread)
Trial: 7796781
Drug: AcNa +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AcNa + Bread (olive oil plus sodium acetate followed by 50 g carbohydrate portions of white bread)
Trial: 2368891
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 40 mg/kg (Group 1)
Trial: 2368891
Drug: Diazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.25 mg/kg (Group 2)
Trial: 2368891
Drug: Alprazolam 0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.005 mg/kg (both groups)
Trial: 2368891
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg/kg (both groups)
Trial: 97705
Drug: Enthusiastic messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enthusiastic messages of drug effects
Trial: 29336900
Drug: Low-dose 99mTc-MIBI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 99mTc-MIBI + NC (group I)
Trial: 29336900
Drug: Low-dose 99mTc-MIBI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 99mTc-MIBI (group II)
Trial: 20101012
Drug: Once-weekly resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly resistance training (n = 54)
Trial: 20101012
Drug: Twice-weekly resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly resistance training (n = 52)
Trial: 20101012
Drug: Twice-weekly balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly balance and tone training (control group, n = 49)
Trial: 12828584
Drug: Aminophylline treatment
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline treatment in group C (n=5)
Trial: 10731502
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg/d for 28 days)
Trial: 7506169
Drug: Nimesulide (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100mg orally, twice daily)
Trial: 7506169
Drug: Piroxicam (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20mg orally, once daily)
Trial: 7506169
Drug: Ketoprofen (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (100mg orally, twice daily)
Trial: 24238032
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 0.2 mg·kg(‐1)
Trial: 24238032
Drug: Promethazine 0.5
RxNorm normalized name: PROMETHAZINE 0.5MG/ML/NACL INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 0.5 mg·kg(‐1)
Trial: 20007307
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (58 mmol . L(‐1) . d(‐1))
Trial: 20007307
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (170 mmol . L(‐1) . d(‐1))
Trial: 20007307
Drug: Urinary aldosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary aldosterone excretion rates
Trial: 14644671
Drug: Intensive peer
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive peer education sessions (20 bi-weekly sessions over 1 year and quarterly booster sessions for 2 years)
Trial: 9690722
Drug: ranitidine 75
RxNorm normalized name: ranitidine 75 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 75 mg
Trial: 26789727
Drug: NPM1-mutated transcripts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPM1-mutated transcripts present after second chemotherapy cycle
Trial: 26789727
Drug: Sequential monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential monitoring of minimal residual disease
Trial: 22913215
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of L-arginine for 3 months
Trial: 12148095
Drug: Intravenous CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CT angiography (CTA)
Trial: 8593974
Drug: Triflusal 300
RxNorm normalized name: triflusal 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal 300 mg twice daily
Trial: 25300507
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy (vPDT)
Trial: 20529984
Drug: Small-dose nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose nefopam (50 ng/mL)
Trial: 20529984
Drug: Large-dose nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose nefopam (100 ng/mL)
Trial: 18824706
Drug: IROX (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IROX (irinotecan 200 mg/m² plus oxaliplatin 85 mg/m²)
Trial: 18824706
Drug: Irinotecan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan alone (350 mg/m²)
Trial: 9459088
Drug: Purified FSH
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified FSH preparation (9 patients, 35 follicular fluid samples)
Trial: 9459088
Drug: FSH-dominant human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FSH-dominant human menopausal gonadotropin (hMG) preparation (9 patients, 34 samples)
Trial: 8182402
Drug: Anticoagulant (AC)
RxNorm normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant (AC) therapy with intravenous heparin infusion for at least 6 days and oral AC therapy for 3 months
Trial: 8182402
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant (non-AC) therapy
Trial: 8182402
Drug: Anticoagulant (AC)
RxNorm normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant (AC) therapy
Trial: 3234438
Drug: Low fat/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat/high malto‐dextrin formula (2.6 g fat/100 ml, 8.1 g carbohydrate/100 ml, 2.8 g malto‐dextrin/100 ml)
Trial: 3234438
Drug: High fat/low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat/low malto‐dextrin formula (3.6 g fat/100 ml, 7.3 g carbohydrate/100 ml, 1.9 g malto‐dextrin/100 ml)
Trial: 29153485
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300U/mL (Gla‐300) at 0.4U/kg/day
Trial: 29153485
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300U/mL (Gla‐300) at 0.6U/kg/day
Trial: 29153485
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100U/mL (Deg‐100) at 0.4U/kg/day
Trial: 29153485
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100U/mL (Deg‐100) at 0.6U/kg/day
Trial: 22676626
Drug: 11-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-valent pneumococcal conjugate vaccine
Trial: 20096138
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 to 40 mg) plus B12 (0.5 mg), B6 (25 mg) and folic acid (2 mg)
Trial: 20096138
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 to 40 mg) plus placebo
Trial: 19008063
Drug: Dual flow
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual flow injection protocol with saline chaser containing 20% contrast media
Trial: 16607927
Drug: Fasting and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting and 2-hour insulin levels
Trial: 12580984
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg day(-1)
Trial: 7682266
Drug: Aprotinin 20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 20,000 U/kg after induction, 20,000 U/kg added to the prime, and 20,000 U/kg every hour during cardiopulmonary bypass (low-dose regimen)
Trial: 7682266
Drug: Aprotinin 35,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 35,000 U/kg after induction followed by an infusion of 10,000 U/kg.min until the end of the operation and 35,000 U/kg added to the prime (high-dose regimen)
Trial: 7682266
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (low-dose aprotinin)
Trial: 24606088
Drug: Weekly iv
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly iv methylprednisolone
Trial: 24606088
Drug: Daily iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iv methylprednisolone
Trial: 20683501
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (25-150 mg equivalents)
Trial: 20683501
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (25-100 mg equivalents)
Trial: 18778865
Drug: Metformin (1000-2000mg/day)
RxNorm normalized name: metformin hydrochloride 1000 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (1000-2000mg/day)
Trial: 15754408
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection with postoperative chemotherapy
Trial: 12066723
Drug: GIK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK group (500 ml of 50% dextrose solution containing 100 IU insulin and potassium 80 mmol infused at 0.75 ml kg(‐1) h(‐1))
Trial: 12066723
Drug: Non-GIK group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-GIK group (5% dextrose solution infused at the same rate)
Trial: 8808179
Drug: Mefloquine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine alone (750 mg)
Trial: 8808179
Drug: Mefloquine in
RxNorm normalized name: Product containing mefloquine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine in combination with artemether (300 mg, given 24 hours prior)
Trial: 18788990
Drug: Isoflavones (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (70 mg) for 6 months
Trial: 10810399
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively (Group A)
Trial: 10810399
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively plus UFT orally at a dose of 400 mg daily for one year (Group B)
Trial: 8857073
Drug: FK613 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK613 5 mg
Trial: 8857073
Drug: FK613 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK613 20 mg
Trial: 8857073
Drug: FK613 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK613 40 mg twice daily for 6.5 days
Trial: 8857073
Drug: FK613 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK613 30 mg or more